<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01914536</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-POM-2013-46</org_study_id>
    <nct_id>NCT01914536</nct_id>
  </id_info>
  <brief_title>A Natural History Study of Adult Onset Pompe Disease Using Muscle MRI</brief_title>
  <acronym>POMPE 2013</acronym>
  <official_title>A Natural History Study of Adult Onset Pompe Disease Using Muscle MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is an observational prospective study in which patients affected by an adult
      onset Pompe disease will be followed-up during three years using different clinical,
      analytical and radiological tests in order to know which is the natural history of the
      disease and which is the impact that treatment with recombinant enzyme has in the progression
      of the disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study aim:

      The principal objective of the study is to find biomarkers that quantify the natural
      progression of the disease and to know if they are useful to determine the improvement or
      lack of impairment of the disease in response to Enzyme Replacement Therapy (ERT).

      Study design:

      A single center observational prospective study.

      Patients:

      Patients with adult onset POMPE disease (onset of symptoms after two years old) and molecular
      diagnosis confirming the disease are eligible

      Methods:

      Clinical information will be obtained according to a pre-defined protocol including six
      visits: screening visit, baseline, 6 month, 12 month, 24 month and 36 month.

      In each visit we will perform the following tests: clinical assessment (including interview
      with patients, quality of live questionnaires, timed tests and assessment of muscle balance
      using a myometer), analytical tests (blood and urine tests), cardiac test (Electrocardiogram
      (ECG) and cardiac echography), respiratory assessment (using spirometer) and skeletal muscle
      imaging (Muscle MRI).

      All data collect will be introduced in a database and afterwards statistically analyzed.

      Expected results:

      We expect to find a biomarker useful to follow-up the progression of Pompe disease. This
      biomarker has to be sensitive to the changes that muscle function may have after treatment
      with ERT.

      Funding:

      This project is funded by Genzyme, a Sanofi company
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in muscle atrophy using muscle MRI in patients with adult onset Pompe disease</measure>
    <time_frame>baseline, 6 months, one year, two years and three years</time_frame>
    <description>To know the natural progression of the disease regarding muscle atrophy measured using muscle MRI during a period of three years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>baseline, 6 months, one year, two years and three years</time_frame>
    <description>To study progression of muscle weakness using manual and informatic devices as myometry. We will compare clinical progression with Muscle MRI results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Micro RNA study</measure>
    <time_frame>baseline, 6 months, one year, two years and three years</time_frame>
    <description>We will obtain blood samples of all the patients to study the microRNA profile and different time points</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pompe Disease</condition>
  <arm_group>
    <arm_group_label>Pompe patients</arm_group_label>
    <description>Adult onset pompe patients being or not treated with enzyme therapy replacement</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood an urine samples will be obtained
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult onset Pompe Patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pompe disease confirmed using genetic study

          -  Onset of symptoms more than 2 years old

          -  To be able to come to the hospital and follow all the visits

          -  Patients with respiratory involvement are welcomed

        Exclusion Criteria:

          -  Patients unable to perform a MRI (respiratory problems can be solved using mechanical
             ventilation)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordi Díaz Manera, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabel Illa, MD pHD</last_name>
    <role>Study Director</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jordi Díaz_Manera, MD PhD</last_name>
    <phone>0034-935565986</phone>
    <phone_ext>5986</phone_ext>
    <email>JDiazM@santpau.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sonia Segovia Simon</last_name>
    <phone>0034-935565978</phone>
    <phone_ext>5978</phone_ext>
    <email>SSegovia@santpau.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de la Santa Creu iSant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi Díaz Manera, MD PhD</last_name>
      <phone>0034-935565986</phone>
      <phone_ext>5986</phone_ext>
      <email>JDiazM@santpau.cat</email>
    </contact>
    <contact_backup>
      <last_name>Sonia Segovia Simon</last_name>
      <phone>0034-935565978</phone>
      <phone_ext>5978</phone_ext>
      <email>SSegovia@santpau.cat</email>
    </contact_backup>
    <investigator>
      <last_name>Jordi Díaz-Manera, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eduard Gallardo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aida Alejaldre, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Izaskun Belmonte</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2013</study_first_submitted>
  <study_first_submitted_qc>July 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2013</study_first_posted>
  <last_update_submitted>August 29, 2013</last_update_submitted>
  <last_update_submitted_qc>August 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>POMPE</keyword>
  <keyword>Glycogenosis type II</keyword>
  <keyword>Acid maltase deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

